| Nasrin Mehvar, | |
|
5921 Hillside Rd, Amarillo, TX 79109-6294 | |
| (806) 463-1057 | |
| (806) 463-3256 |
| Full Name | Nasrin Mehvar |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 5921 Hillside Rd, Amarillo, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043547987 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 38539 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Nasrin Mehvar, 5921 Hillside Rd, Amarillo, TX 79109-6294 Ph: (806) 463-1057 | Nasrin Mehvar, 5921 Hillside Rd, Amarillo, TX 79109-6294 Ph: (806) 463-1057 |
News Archive
Curing disease with neutrophils; this is the goal of the NeutroCure project. How will that work? "Neutrophils have a yin yang character," explained Andrés Hidalgo, whose team at the Centro Nacional de Investigaciones Cardiovasculares is one of six member groups participating in this project coordinated by Andriy Mokhir Friedrich from Alexander University, Germany.
Research of the common tuberculosis (TB) drug pyrazinamide, which is used in combination with other medications to treat the disease in a six-month regimen, "has now revealed that the drug does kill the latent form of the microbe, which does not cause observable symptoms," VOA News reports.
Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that an interim analysis of all 86 patients enrolled in the company's Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps for severe cases of COVID-19.
› Verified 8 days ago
Tonya Olson, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2035 Se 34th Ave, Amarillo, TX 79118 Phone: 806-513-6401 Fax: 806-513-6398 | |
Mr. Robert Medina Jr., B.S.-R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6010 Amarillo Blvd West, Amarillo, TX 79106 Phone: 806-354-7898 Fax: 806-354-7857 | |
Justin Levi Cooper, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5709 W Amarillo Blvd, Amarillo, TX 79106 Phone: 806-355-7209 | |
Nathaniel Sveter, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 801 N Fillmore St, Amarillo, TX 79107 Phone: 806-371-8116 | |
Dr. Owen G. Kennedy, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3324 S Georgia St, Amarillo, TX 79109 Phone: 806-352-2711 | |
Dr. Kristina Renea Thomason, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1500 Wallace Blvd, Amarillo, TX 79106 Phone: 806-212-1945 | |
Neha K Vora, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3320 Bell St, Amarillo, TX 79106 Phone: 806-468-6150 |